Other · developed by Crescent Biopharma
CR-002 is a drug studied in head and neck squamous cell carcinoma, gastric or gastroesophageal junction cancer, biliary tract cancer, esophageal squamous cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, and non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07909031 | Phase 1/2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Recruiting | CBIO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Biliary Tract Cancer (BTC)Cervical Cancer MetastaticEndometrial CancerEsophageal Squamous Cell Carcinoma (ESCC)Gastric/GEJNon-small Cell Lung Cancer (NSCLC)Ovarian Cancer
See CBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CBIO catalysts and pipeline →